- Category
- Medium (2026-27)
- Udyam number
- UDYAM-MH-18-0208449

About Genpharmasec Limited
Data last updated:
Genpharmasec Limited is a public limited company based in Mumbai, Maharashtra, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 16 November 1992 and has been in existence for over 34 years.
The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN L24231MH1992PLC323914. Its GSTIN is 27AABCA8318D2ZX (Maharashtra). The company holds 2 GST registrations, of which 1 is active. It is a listed company as per MCA records. Its shares are listed on BSE: 531592.
The company has an authorised share capital of ₹56 Cr and a paid-up capital of ₹55.37 Cr. It was formerly known as Generic Pharmasec Limited and Adi Rasayan Limited. It is led by directors including Sohan Chaturvedi (Whole-Time Director) and Mayur Bharatbhai Bhatt.
Its last annual general meeting (AGM) was held on 29 September 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at Mumbai, Maharashtra.
As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹139.94 Cr, reflecting significant growth compared to the previous year. For the same year it recorded a net profit of ₹1.6 Cr (net margin 1.1%) and EBITDA of ₹1.22 Cr (EBITDA margin 0.9%). The net worth stands at ₹66.26 Cr (up 1.7% YoY). Total assets are valued at ₹100.73 Cr (up 42.7% YoY).
The company is associated with 1 brand: Genpharmasec. As per MCA filings, the company has open charges of ₹12.5 Cr and satisfied charges of ₹30.35 Cr on record. Court records list 6 cases involving the company, including 1 filed by the company and 5 filed against it. The company has 48 deals on record (47 market trades, 1 funding round), with disclosed funding of ₹48.45 Cr; the latest was in August 2026. Its 3 peer companies in the BFSI industry (Broking Services, Healthcare Equipment Retail and Distribution), with the same principal business activity (wholesale trading) are compared by revenue, 2 larger and 1 smaller; the largest is Imaging Products (India) Private Limited with revenue of ₹36.97 Cr. The company has 1 MSME Form 1 return on record for the period ending Sep 2019, listing 2 overdue payments to 1 micro and small supplier.
Genpharmasec Limited is registered as a medium enterprise under the Udyam registration framework (Reg. No. UDYAM-MH-18-0208449). The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website genpharmasec.com.
Company details
Name history
Genpharmasec has undergone 3 name changes throughout its history. The company was previously known as Generic Pharmasec Limited, Adi Rasayan Limited, and Sun Face Pharmasec Limited. The current legal name is Genpharmasec Limited.
| Company Name | Status |
|---|---|
| Genpharmasec Limited | Current |
| Generic Pharmasec Limited | Previous |
| Adi Rasayan Limited | Previous |
| Sun Face Pharmasec Limited | Previous |
CIN history
Genpharmasec has one previous CIN (Corporate Identification Number): L24231GJ1992PLC018572. The current CIN is L24231MH1992PLC323914, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L24231MH1992PLC323914 | Current |
| L24231GJ1992PLC018572 | Previous |
Recognitions & Rankings of Genpharmasec
Contact details
Genpharmasec Limited's registered office is in Mumbai, Maharashtra. Its website is genpharmasec.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Registered AddressOffice No. 104 & 105 1st Floor Gundecha Industrial Premises Co – Op Soc. Ltd.Akurli Road Kand, Ivali East, Mumbai, Maharashtra, India – 400101
- IndustryPharma, Drug Formulation & Development
To see the full contact details of Genpharmasec Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Brands
Genpharmasec operates one associated brand: Genpharmasec. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Pharmaceutical products and services are provided and distributed. | genpharmasec.com |
Business activity
The main business activity of Genpharmasec is trade. In detail, this covers wholesale trading.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| G | Trade | G1 | Wholesale Trading |
To see the full business activity and turnover split of Genpharmasec Limited, buy the company report.
Financials of Genpharmasec Limited
FY 2025-26 filings availableGenpharmasec Limited reported revenue of ₹139.94 Cr (up 315% YoY) for FY 2025-26.
Financial Highlights
FY 2025-26 · ConsolidatedRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | 140 | 33.72 | 30.41 | 25.52 |
| Revenue growth | +315.0% | +10.9% | +19.2% | - |
| EBITDA | 1.22 | 0.07 | 0.06 | 0.26 |
| EBITDA margin | +0.9% | +0.2% | +0.2% | +1.0% |
| Profit before tax | 0.97 | 1.87 | 0.27 | 0.28 |
| Net profit | 1.60 | 1.22 | (0.15) | 1.12 |
| Net profit margin | +1.1% | +3.6% | -0.5% | +4.4% |
| EPS (₹) | 0.01 | 0.02 | 0.00 | 0.04 |
| Balance sheet | ||||
| Total assets | 101 | 70.57 | 68.42 | 18.41 |
| Net worth | 66.26 | 65.16 | 64.39 | 15.33 |
| Total debt | 34.95 | 5.28 | 3.89 | 3.08 |
| Cash & bank | 10.07 | 5.27 | 18.83 | 1.99 |
| Net working capital | 43.10 | 17.11 | 36.58 | 16.51 |
| Cash flow | ||||
| Cash from operations | (17.55) | 2.95 | (2.95) | (3.06) |
| Cash from investing | 13.26 | (4.22) | (28.06) | 0.36 |
| Cash from financing | 3.92 | (1.25) | 47.85 | 3.08 |
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 85.66 | 49.71 | 55.43 | 39.83 | 32.64 | 12.04 | 14.01 | 8.48 |
| Revenue growth (YoY) | +162.4% | +312.9% | +295.7% | +369.7% | +441.3% | +131.5% | - | - |
| Other income | 1.06 | 0.37 | 1.02 | 0.98 | 0.46 | 0.69 | 0.94 | 0.81 |
| EBITDA | 1.64 | 0.96 | 1.99 | (1.24) | (0.47) | 0.94 | (1.00) | 0.71 |
| EBITDA margin | +1.9% | +1.9% | +3.6% | -3.1% | -1.4% | +7.8% | -7.1% | +8.4% |
| Depreciation | 0.68 | 0.67 | 0.68 | 0.67 | 0.56 | 0.27 | 0.26 | 0.10 |
| Interest | 0.44 | 0.40 | 0.48 | 0.41 | 0.23 | 0.12 | 0.11 | 0.16 |
| Profit before tax | 1.58 | 0.26 | 1.85 | (1.34) | (0.80) | 1.24 | (0.43) | 1.26 |
| Tax | 0.55 | 0.43 | 0.50 | (0.50) | 0.38 | 0.03 | (0.16) | 0.51 |
| Net profit | 1.03 | (0.17) | 1.35 | (0.84) | (1.18) | 1.21 | (0.27) | 0.75 |
| EPS (₹) | 0.01 | 0.00 | 0.02 | (0.02) | (0.02) | 0.02 | (0.01) | 0.01 |
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 131 | 32.96 | 30.41 | 25.52 | 27.32 | 21.31 | 16.50 |
| Revenue growth | +298.5% | +8.4% | +19.2% | -6.6% | +28.2% | +29.2% | - |
| EBITDA | 2.42 | 0.44 | 0.18 | 0.26 | (0.51) | 1.19 | 0.64 |
| EBITDA margin | +1.8% | +1.3% | +0.6% | +1.0% | -1.9% | +5.6% | +3.9% |
| Profit before tax | 6.44 | 3.45 | 0.49 | 0.28 | (0.43) | 1.51 | 1.20 |
| Net profit | 5.46 | 2.47 | 0.07 | 1.12 | (0.20) | 1.26 | 1.00 |
| Net profit margin | +4.2% | +7.5% | +0.2% | +4.4% | -0.7% | +5.9% | +6.1% |
| EPS (₹) | 0.10 | 0.04 | 0.00 | 0.04 | (0.01) | 0.05 | 0.05 |
| Balance sheet | |||||||
| Total assets | 76.54 | 69.98 | 67.78 | 18.41 | 15.37 | 20.66 | 19.03 |
| Net worth | 71.49 | 66.55 | 64.57 | 15.33 | 15.37 | 20.67 | 19.04 |
| Total debt | 4.98 | 3.43 | 3.21 | 3.08 | 0.00 | 0.00 | 0.00 |
| Cash & bank | 9.29 | 5.14 | 18.58 | 1.99 | 1.61 | 3.53 | 2.58 |
| Net working capital | 28.27 | 17.82 | 35.65 | 16.51 | 12.82 | 11.95 | 7.87 |
| Cash flow | |||||||
| Cash from operations | 1.93 | 0.96 | (2.27) | (3.06) | (2.34) | (2.13) | 1.39 |
| Cash from investing | (1.64) | (2.92) | (29.03) | 0.36 | 0.42 | (1.41) | (4.01) |
| Cash from financing | (0.02) | (0.44) | 47.89 | 3.08 | 0.00 | 4.50 | 0.00 |
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 50.83 | 44.78 | 51.66 | 36.01 | 31.56 | 12.11 | 13.56 | 8.34 |
| Revenue growth (YoY) | +61.1% | +269.8% | +281.0% | +331.8% | +447.0% | +128.5% | - | - |
| Other income | 1.66 | 0.97 | 1.62 | 1.43 | 1.00 | 0.82 | 1.06 | 0.93 |
| Total expenses | 49.18 | 43.43 | 50.08 | 36.68 | 31.06 | 11.11 | 14.55 | 7.40 |
| EBITDA | 1.65 | 1.35 | 1.58 | (0.67) | 0.50 | 1.00 | (0.99) | 0.94 |
| EBITDA margin | +3.2% | +3.0% | +3.1% | -1.9% | +1.6% | +8.3% | -7.3% | +11.3% |
| Depreciation | 0.10 | 0.10 | 0.09 | 0.07 | 0.04 | 0.04 | 0.04 | 0.05 |
| Interest | 0.16 | 0.13 | 0.25 | 0.19 | 0.08 | 0.08 | 0.06 | 0.11 |
| Profit before tax | 3.05 | 2.09 | 2.86 | 0.50 | 1.38 | 1.70 | (0.03) | 1.71 |
| Tax | 0.49 | 0.53 | 0.55 | (0.27) | 0.57 | 0.15 | 0.20 | 0.61 |
Financial Statements
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 85.66 | 49.71 | 55.43 | 39.83 | 32.64 | 12.04 | 14.01 | 8.48 |
| Revenue growth (YoY) | +162.4% | +312.9% | +295.7% | +369.7% | +441.3% | +131.5% | - | - |
| Other income | 1.06 | 0.37 | 1.02 | 0.98 | 0.46 | 0.69 | 0.94 | 0.81 |
| EBITDA | 1.64 | 0.96 | 1.99 | (1.24) | (0.47) | 0.94 | (1.00) | 0.71 |
| EBITDA margin | +1.9% | +1.9% | +3.6% | -3.1% | -1.4% | +7.8% | -7.1% | +8.4% |
| Depreciation | 0.68 | 0.67 | 0.68 | 0.67 | 0.56 | 0.27 | 0.26 | 0.10 |
| Interest | 0.44 | 0.40 | 0.48 | 0.41 | 0.23 | 0.12 | 0.11 | 0.16 |
| Profit before tax | 1.58 | 0.26 | 1.85 | (1.34) | (0.80) | 1.24 | (0.43) | 1.26 |
| Tax | 0.55 | 0.43 | 0.50 | (0.50) | 0.38 | 0.03 | (0.16) | 0.51 |
| Net profit | 1.03 | (0.17) | 1.35 | (0.84) | (1.18) | 1.21 | (0.27) | 0.75 |
| EPS (₹) | 0.01 | 0.00 | 0.02 | (0.02) | (0.02) | 0.02 | (0.01) | 0.01 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 |
|---|---|---|---|---|
| Revenue | 140 | 33.72 | 30.41 | 25.52 |
| Revenue growth | +315.0% | +10.9% | +19.2% | - |
| Other income | 3.16 | 3.06 | 0.66 | 0.10 |
| Total expenses | 139 | 33.65 | 30.35 | 25.26 |
| Employee cost | 0.00 | 0.99 | 0.76 | 0.54 |
| EBITDA | 1.22 | 0.07 | 0.06 | 0.26 |
| EBITDA margin | +0.9% | +0.2% | +0.2% | +1.0% |
| Depreciation | 2.17 | 0.81 | 0.04 | 0.02 |
| Interest | 1.24 | 0.45 | 0.41 | 0.06 |
| Profit before tax | 0.97 | 1.87 | 0.27 | 0.28 |
| Tax | 0.41 | 0.65 | 0.42 | (0.84) |
| Net profit | 1.60 | 1.22 | (0.15) | 1.12 |
| Net profit margin | +1.1% | +3.6% | -0.5% | +4.4% |
| EPS (₹) | 0.01 | 0.02 | 0.00 | 0.04 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 |
|---|---|---|---|---|
| Equity & liabilities | ||||
| Share capital | 55.37 | 55.37 | 55.37 | 27.69 |
| Reserves & surplus | 10.89 | 9.79 | 9.02 | (12.36) |
| Shareholders' funds (net worth) | 66.26 | 65.16 | 64.39 | 15.33 |
| Minority interest | (0.62) | 0.12 | 0.14 | 0.00 |
| Secured loans | 1.08 | 0.00 | 0.00 | 0.00 |
| Unsecured loans | 33.87 | 5.28 | 3.89 | 3.08 |
| Total debt | 34.95 | 5.28 | 3.89 | 3.08 |
| Total liabilities | 101 | 70.57 | 68.42 | 18.41 |
| Assets | ||||
| Gross block | 47.84 | 8.48 | 0.93 | 0.15 |
| Net block | 41.25 | 7.59 | 0.83 | 0.10 |
| Capital work in progress | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 1.58 | 19.73 | 19.32 | 0.95 |
| Inventories | 13.88 | 7.30 | 8.84 | 9.68 |
| Sundry debtors | 29.27 | 13.60 | 9.10 | 5.71 |
| Cash & bank balances | 10.07 | 5.27 | 18.83 | 1.99 |
| Loans & advances | 27.30 | 0.25 | 2.51 | 0.59 |
| Total current assets | 80.52 | 26.42 | 39.28 | 17.97 |
| Total current liabilities | 37.42 | 9.31 | 2.70 | 1.46 |
| Net working capital | 43.10 | 17.11 | 36.58 | 16.51 |
| Total assets | 101 | 70.57 | 68.42 | 18.41 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 |
|---|---|---|---|---|
| Opening cash | 1.34 | 3.17 | 1.99 | 1.61 |
| Net cash from operating activities | (17.55) | 2.95 | (2.95) | (3.06) |
| Net cash from investing activities | 13.26 | (4.22) | (28.06) | 0.36 |
| Net cash from financing activities | 3.92 | (1.25) | 47.85 | 3.08 |
| Net change in cash | (0.37) | (2.52) | 16.84 | 0.39 |
| Closing cash | 10.07 | 5.27 | 18.83 | 1.99 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 |
|---|---|---|---|---|
| Growth | ||||
| Sales growth | +315.0% | +10.9% | +19.2% | - |
| EBITDA growth | +1642.9% | +16.7% | -76.9% | - |
| PBT growth | -56.8% | +722.2% | -3.6% | +9997.0% |
| Net income growth | +31.2% | +913.3% | -113.4% | - |
| Revenue CAGR (3Y) | +76.3% | - | - | - |
| EBITDA CAGR (3Y) | +67.0% | - | - | - |
| Profitability & leverage | ||||
| Net income margin | +0.4% | +4.7% | -0.5% | +4.4% |
| Return on capital employed | +2.5% | +3.7% | 0.0% | +1.5% |
| Return on net worth | +0.8% | +2.4% | 0.0% | +5.6% |
| Debt / equity | 0.31 | 0.07 | 0.09 | 0.20 |
| Long-term debt / equity | 0.23 | 0.07 | 0.08 | 0.16 |
| Interest cover | -129.17 | -104.88 | 2,050.00 | 25.00 |
| Efficiency & per share | ||||
| Fixed asset turnover | 4.97 | 7.17 | 56.31 | 170.13 |
| Inventory turnover | 13.21 | 4.18 | 3.28 | 2.64 |
| Debtors turnover | 6.53 | 2.97 | 4.11 | 4.47 |
| EPS (₹) | 0.03 | 0.03 | 0.00 | 0.04 |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 1.20 | 1.18 | 1.16 | 0.55 |
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 50.83 | 44.78 | 51.66 | 36.01 | 31.56 | 12.11 | 13.56 | 8.34 |
| Revenue growth (YoY) | +61.1% | +269.8% | +281.0% | +331.8% | +447.0% | +128.5% | - | - |
| Other income | 1.66 | 0.97 | 1.62 | 1.43 | 1.00 | 0.82 | 1.06 | 0.93 |
| Total expenses | 49.18 | 43.43 | 50.08 | 36.68 | 31.06 | 11.11 | 14.55 | 7.40 |
| EBITDA | 1.65 | 1.35 | 1.58 | (0.67) | 0.50 | 1.00 | (0.99) | 0.94 |
| EBITDA margin | +3.2% | +3.0% | +3.1% | -1.9% | +1.6% | +8.3% | -7.3% | +11.3% |
| Depreciation | 0.10 | 0.10 | 0.09 | 0.07 | 0.04 | 0.04 | 0.04 | 0.05 |
| Interest | 0.16 | 0.13 | 0.25 | 0.19 | 0.08 | 0.08 | 0.06 | 0.11 |
| Profit before tax | 3.05 | 2.09 | 2.86 | 0.50 | 1.38 | 1.70 | (0.03) | 1.71 |
| Tax | 0.49 | 0.53 | 0.55 | (0.27) | 0.57 | 0.15 | 0.20 | 0.61 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 131 | 32.96 | 30.41 | 25.52 | 27.32 | 21.31 | 16.50 |
| Revenue growth | +298.5% | +8.4% | +19.2% | -6.6% | +28.2% | +29.2% | - |
| Other income | 4.87 | 3.43 | 0.72 | 0.10 | 0.09 | 0.33 | 0.56 |
| Total expenses | 129 | 32.52 | 30.23 | 25.26 | 27.83 | 20.12 | 15.86 |
| Employee cost | 0.00 | 0.67 | 0.76 | 0.54 | 0.25 | 0.19 | 0.13 |
| EBITDA | 2.42 | 0.44 | 0.18 | 0.26 | (0.51) | 1.19 | 0.64 |
| EBITDA margin | +1.8% | +1.3% | +0.6% | +1.0% | -1.9% | +5.6% | +3.9% |
| Depreciation | 0.26 | 0.13 | 0.02 | 0.02 | 0.01 | 0.01 | 0.00 |
| Interest | 0.59 | 0.29 | 0.39 | 0.06 | 0.00 | 0.00 | 0.00 |
| Profit before tax | 6.44 | 3.45 | 0.49 | 0.28 | (0.43) | 1.51 | 1.20 |
| Tax | 0.98 | 0.98 | 0.42 | (0.84) | (0.23) | 0.25 | 0.20 |
| Net profit | 5.46 | 2.47 | 0.07 | 1.12 | (0.20) | 1.26 | 1.00 |
| Net profit margin | +4.2% | +7.5% | +0.2% | +4.4% | -0.7% | +5.9% | +6.1% |
| EPS (₹) | 0.10 | 0.04 | 0.00 | 0.04 | (0.01) | 0.05 | 0.05 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 55.37 | 55.37 | 55.37 | 27.69 | 27.69 | 27.69 | 21.69 |
| Reserves & surplus | 16.12 | 11.18 | 9.20 | (12.36) | (12.32) | (7.02) | (4.15) |
| Shareholders' funds (net worth) | 71.49 | 66.55 | 64.57 | 15.33 | 15.37 | 20.67 | 19.04 |
| Secured loans | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Unsecured loans | 4.98 | 3.43 | 3.21 | 3.08 | 0.00 | 0.00 | 0.00 |
| Total debt | 4.98 | 3.43 | 3.21 | 3.08 | 0.00 | 0.00 | 0.00 |
| Total liabilities | 76.54 | 69.98 | 67.78 | 18.41 | 15.37 | 20.66 | 19.03 |
| Assets | |||||||
| Gross block | 1.24 | 0.45 | 0.17 | 0.15 | 0.14 | 0.07 | 0.05 |
| Net block | 1.13 | 0.36 | 0.10 | 0.10 | 0.11 | 0.05 | 0.04 |
| Capital work in progress | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 21.67 | 20.84 | 19.52 | 0.95 | 2.45 | 7.81 | 5.76 |
| Inventories | 12.58 | 7.24 | 8.84 | 9.68 | 9.89 | 7.68 | 3.46 |
| Sundry debtors | 28.02 | 13.39 | 9.10 | 5.71 | 6.45 | 7.52 | 7.03 |
| Cash & bank balances | 9.29 | 5.14 | 18.58 | 1.99 | 1.61 | 3.53 | 2.58 |
| Loans & advances | 11.89 | 1.16 | 1.83 | 0.59 | 1.15 | 0.38 | 0.53 |
| Total current assets | 61.78 | 26.93 | 38.35 | 17.97 | 19.10 | 19.11 | 13.60 |
| Total current liabilities | 33.51 | 9.11 | 2.70 | 1.46 | 6.28 | 7.16 | 5.73 |
| Net working capital | 28.27 | 17.82 | 35.65 | 16.51 | 12.82 | 11.95 | 7.87 |
| Total assets | 76.54 | 69.98 | 67.78 | 18.41 | 15.37 | 20.66 | 19.03 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 0.52 | 2.92 | 1.99 | 1.61 | 3.53 | 2.58 | 5.20 |
| Net cash from operating activities | 1.93 | 0.96 | (2.27) | (3.06) | (2.34) | (2.13) | 1.39 |
| Net cash from investing activities | (1.64) | (2.92) | (29.03) | 0.36 | 0.42 | (1.41) | (4.01) |
| Net cash from financing activities | (0.02) | (0.44) | 47.89 | 3.08 | 0.00 | 4.50 | 0.00 |
| Net change in cash | 0.27 | (2.39) | 16.59 | 0.39 | (1.93) | 0.96 | (2.62) |
| Closing cash | 9.29 | 5.14 | 18.58 | 1.99 | 1.61 | 3.53 | 2.58 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +298.5% | +8.4% | +19.2% | -6.6% | +28.2% | +29.2% | - |
| EBITDA growth | +450.0% | +144.4% | -30.8% | +151.0% | -142.9% | +85.9% | - |
| PBT growth | +70.6% | +669.4% | +75.0% | +9998.0% | - | +25.8% | +328.6% |
| Net income growth | +121.1% | +3428.6% | -93.8% | +660.0% | -115.9% | +26.0% | - |
| Revenue CAGR (3Y) | +72.7% | +6.5% | +12.6% | +15.7% | +315.8% | +543.4% | +225.2% |
| EBITDA CAGR (3Y) | +110.1% | - | -46.7% | -25.9% | +78.3% | - | - |
| Profitability & leverage | |||||||
| Net income margin | +4.2% | +8.5% | +0.2% | +4.4% | -0.7% | +5.9% | +6.1% |
| Return on capital employed | +9.5% | +5.6% | +1.8% | +1.8% | 0.0% | +7.6% | +5.8% |
| Return on net worth | +7.8% | +4.1% | +0.1% | +6.4% | 0.0% | +6.4% | +4.9% |
| Debt / equity | 0.06 | 0.05 | 0.08 | 0.10 | 0.00 | 0.00 | 0.00 |
| Long-term debt / equity | 0.06 | 0.05 | 0.07 | 0.08 | 0.00 | 0.00 | 0.00 |
| Interest cover | 27.44 | 45.16 | 243.75 | 25.00 | 0.00 | 0.00 | 0.00 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 155.44 | 106.32 | 190.06 | 176.00 | 260.19 | 355.17 | 550.00 |
| Inventory turnover | 13.25 | 4.10 | 3.28 | 2.61 | 3.11 | 3.83 | 9.54 |
| Debtors turnover | 6.34 | 2.93 | 4.11 | 4.20 | 3.91 | 2.93 | 4.67 |
| EPS (₹) | 0.10 | 0.05 | 0.00 | 0.04 | (0.01) | 0.05 | 0.05 |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 1.29 | 1.20 | 1.17 | 0.55 | 0.56 | 0.75 | 0.81 |
To see the full year-wise statements and ratios of Genpharmasec Limited, buy the company report.
Board of directors and KMP of Genpharmasec Limited
Genpharmasec Limited currently reports 6 directors and 1 key managerial person. 18 former directors have served the organization.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Mayur Bharatbhai Bhatt Also directs: R M Drip and Sprinklers Systems Limited | Director | 01 Nov 2022 | 4 Years 0 Months | Current |
| Sachin Prakash Aphandkar | Director | 01 Nov 2022 | 4 Years 0 Months | Current |
| Hardik Pravinbhai Makwana | Company Secretary | 27 Mar 2024 | 2 Years 7 Months | Current |
| Siddhesh Shankar Shende Also directs: Clinigenome India Private Limited, Muzali Arts Limited | Director | 04 Jul 2022 | 4 Years 4 Months | Current |
| Sohan Chaturvedi | Whole-Time Director | 26 Apr 2024 | 2 Years 6 Months | Current |
| Rajesh Mirchumal Sadhwani | Director | 02 Jan 2019 | 7 Years 10 Months | Current |
Peer comparison
Genpharmasec Limited is compared with the 3 companies closest to it by revenue in the BFSI industry (Broking Services, Healthcare Equipment Retail and Distribution), with the same principal business activity (wholesale trading), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Genpharmasec Limitedthis company | ₹139.94 Cr (FY 2026) | ₹1.6 Cr | 1.1% | 315.0% | Mumbai, Maharashtra, India | |
| Imaging Products (India) Private Limited | ₹36.97 Cr (FY 2024) | -6.0% | Chennai, Tamil Nadu, India | |||
| Nexnos Pharma Limited | ₹36.91 Cr (FY 2025) | 187.0% | Chittorgarh, Rajasthan, India | |||
| Mamta Hygiene Products Private Limited | ₹36.68 Cr (FY 2025) | 76.0% | Gulabpura, Rajasthan, India |
To see the full peer comparison of Genpharmasec Limited, buy the company report.
Auditor
Genpharmasec Limited is audited by Abhishek S Tiwari & Associates for the financial year 2023.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| Abhishek S Tiwari & Associates | FY 2023 | 141048W |
Shareholding
Shareholding for the quarter ended Sep 2026: promoters hold 30.00%, foreign institutional investors hold 0.00%, domestic institutional investors hold 0.00% and retail and other public shareholders hold 70.00%.
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | |
|---|---|---|---|---|
| Promoters | 30.00% | 30.00% | 30.00% | 30.00% |
| Public | 70.00% | 70.00% | 70.00% | 70.00% |
Charges & borrowings
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 20 Dec 2025 | 101210453 | Hdfc Bank Limited | ₹10 Cr | Open | |
| 06 May 2025 | 101108946 | Others | ₹2.5 Cr | Open | |
| 03 Jul 2025 | 101120161 | Hdfc Bank Limited | ₹1.5 Cr | Satisfied | |
| 23 May 2025 | 101104542 | Hdfc Bank Limited | ₹2.5 Cr | Satisfied | |
| 24 May 2023 | 100721350 | Others | ₹3 Cr | Satisfied |
To see the full charge records of Genpharmasec Limited, buy the company report.
Total charge records: 9 View all charges
Deals & funding
Genpharmasec Limited has 48 deals on record (47 market trades, 1 funding round), with disclosed funding of ₹48.45 Cr; the latest was in August 2026.
Deals on record (5 of 48)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Sep 2024 | Market trade | ₹94.6 Lakh | Seller: Multiplier Share and Stock Advisors Private Limited |
| Sep 2024 | Market trade | ₹97.2 Lakh | Buyer: Multiplier Share and Stock Advisors Private Limited Seller: Multiplier Share and Stock Advisors Private Limited |
| Aug 2024 | Market trade | ₹2.96 Cr | Buyer: Ishaan Tradefin LLP , Mansi Share and Stock Broking Private Limited Seller: Ishaan Tradefin LLP |
| Aug 2024 | Market trade | ₹3.32 Cr | Buyer: Stallion Wealth Management LLP , Ishaan Tradefin LLP Seller: Ishaan Tradefin LLP , Stallion Wealth Management LLP |
| Apr 2024 | Market trade | ₹80.7 Lakh | Seller: Mansi Share and Stock Broking Private Limited |
To see the full deal history of Genpharmasec Limited, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Genpharmasec Limited has 6 court cases on record: 1 filed by Genpharmasec, 5 filed against it. All cases are disposed.
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| District courts | 5 | 5 | 0 |
| High courts | 1 | 0 | 0 |
Cases on record (3 of 6)
| Court | Type of case | Party | Status |
|---|---|---|---|
| High Court, GUJARAT | Court case (COMP) | Filed by the company | Disposed |
| District court, Ahmedabad, Gujarat | Criminal complaint | Filed against the company by Registrar of Companies | Disposed |
| District court, Ahmedabad, Gujarat | Court case (CS CCC) | Filed against the company by Ms.Remik Trading Corporation | Disposed |
To see the full case history of Genpharmasec Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME payment delays
Genpharmasec Limited has 1 MSME Form 1 return on record for the period ending Sep 2019, listing 2 overdue payments to 1 micro and small supplier. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (1 of 1)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| Satellite Corporate Services P Ltd |
To see the full MSME payment records of Genpharmasec Limited, buy the company report.
Individuals and sole proprietors among the suppliers are not named.
GST
Genpharmasec has 2 GST registrations: 1 active and 1 cancelled or inactive.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 27AABCA8318D2ZX | Maharashtra | Active | 11 Nov 2017 |
To see the full GST registrations and return filing status of Genpharmasec Limited, buy the company report.
Recent activity
Genpharmasec Limited has 23 board changes on record since 2012: 7 appointments and 16 cessations. The latest: Sohan Chaturvedi was appointed as Whole-Time Director on 26 Apr 2024.
34 earlier events are in the company report.
News
Frequently asked questions
Genpharmasec is an active public limited company based in Mumbai, Maharashtra, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 16 November 1992 (34+ years old) and is registered under CIN L24231MH1992PLC323914. Listed on BSE: 531592.
Genpharmasec reported revenue of ₹139.94 Cr for FY 2025-26 (up 315% YoY) based on consolidated financials.
Genpharmasec has 7 current directors and KMP:
- Sohan Chaturvedi - Whole-Time Director
- Mayur Bharatbhai Bhatt - Director
- Sachin Prakash Aphandkar - Director
- Siddhesh Shankar Shende - Director
- Rajesh Mirchumal Sadhwani - Director
- Sneha Sadhwani - Director
- Hardik Pravinbhai Makwana - Company Secretary
The latest financial statements of Genpharmasec on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 29 September 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of Genpharmasec is 27AABCA8318D2ZX, registered in Maharashtra. The company has 2 GST registrations in all, of which 1 is active and 1 is cancelled or inactive.
The CIN (Corporate Identification Number) of Genpharmasec is L24231MH1992PLC323914. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Yes. Genpharmasec is a listed company as per MCA records. Its shares are listed on BSE (code: 531592).
Genpharmasec has 6 court cases on record: 1 filed by the company and 5 filed against it. Most are in the district courts.
Genpharmasec was incorporated on 16 November 1992, making it 34+ years old. It is registered with the Registrar of Companies, Mumbai.
Genpharmasec has 48 deals on record (47 market trades, 1 funding round), with disclosed funding of ₹48.45 Cr; the latest was in August 2026.
The peers of Genpharmasec by revenue are Imaging Products (India) Private Limited, Nexnos Pharma Limited, Mamta Hygiene Products Private Limited, all in the BFSI industry (Broking Services, Healthcare Equipment Retail and Distribution), with the same principal business activity (wholesale trading).
Sohan Chaturvedi was appointed as Whole-Time Director on 26 Apr 2024. Hardik Pravinbhai Makwana was appointed as Company Secretary on 27 Mar 2024. Heta Viraj Shah ceased to be Company Secretary on 20 Mar 2024. Genpharmasec has 23 board changes on record in total.

